Thank you to our speakers, sponsors, and delegates who joined us in Berlin for the summit! If you are interested in the 2025 event, please get in touch

Your Next Event in the Series:

Who's was in the Room?

Expediting Approval of Novel Inflammatory Dermatology Therapeutics in Europe with Robust Clinical Evidence & Superior Efficacy

The 5th Dermatology Drug Development Summit Europe!

Going Beyond Symptomatic Treatment: Uncovering Targetable Pathways, Translational Techniques & Navigating European Healthcare Infrastructure to Advance Novel R&D for Small Molecules, Biologics, mAb’s & beyond!

The huge unmet need for more efficacious and durable therapies in inflammatory-mediated dermatological diseases reinforced the critical importance of the community uniting at the 5th Dermatology Drug Development Summit Europe, to collaboratively address the prevailing barriers facing pipeline progression and patient access in Europe.

With successful clinical readouts from pharma’s targeting of a range of inflammatory mechanisms coming thick and fast, novel drug targets emerging and exciting advances in biomarker-driven drug development, the therapeutic promise for pipelines to achieve superior efficacy and safety for target patient populations was at an all-time high.

This was your only industry-led forum uniting large pharma, biotech, academic and clinician KOLs under the common goal to translate cutting edge R&D towards long term improvements in patient QoL whilst navigating complex European healthcare infrastructure for transforming clinical practice.

Attendees joined renowned leaders including Sanofi, Nektar Therapeutics and Moonlake Therapeutics to gain unrivalled insight into pipeline strategies translating Psoriasis and Atopic Dermatitis successes, to first-in-class treatments for itch, Prurigo Nodularis, Acne, Hidradenitis Suppurativa, Chronic Spontaneous Urticaria and more!

This was your definitive platform, pairing ground-breaking research with expert-led intelligence to evolve your dermatology portfolio, be equipped to deliver novel therapies with superior and long-lasting efficacy in April 2024!

2024 Speaker Faculty Includes:

Jonathan Zalevsky

Chief Research & Development Officer

Nektar Therapeutics

Kristian Reich

Chief Scientific Officer

MoonLake Immunotherapeutics

Prista Charuworn

Executive Director, Inflammation and Global Development Lead


Simmi Wiggins

Global Lead - Immunology and Medical


Tamar Ben Yedidia

CSO and clinical management

Scinai Immunotherapeutics

What past attendees had to say about their event experience:

“Good quality of presentations. Participants had a strong commitment to dermatology and the advancement of science in the field.”

Michael Herbig, Chief Executive Officer, RaDes GmbH

“Great opportunity to meet KOL (icebreaking, roundtable, small-size event) and great opportunity to learn on the evolution of the market”

Christel Boudry, Business Development, Straticell

2024 Partners:

Previous Attending Companies Include:

Untitled design (8)